EHA 2021: The Current Role of BTK Inhibitors in CLL

Download this slideset to review the latest European perspectives on the role of BTK inhibitors for patients with CLL.
Paolo Ghia, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.21 MB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Related Content

Commentary from Dr. John Leonard on factors he uses to select mantle cell lymphoma therapy, from Clinical Care Options (CCO)

John P. Leonard, MD Released: July 29, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Clinical commentary featuring expert insights on key CLL studies with BTK inhibitors from ASCO and EHA 2021 from Clinical Care Options (CCO)

Anthony Mato, MD, MSCE William G. Wierda, MD, PhD Released: July 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue